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Objectives. Our aim was to evaluate the possible association between homocysteine levels and peripheral arterial disease
(PAD) in a population-based study of Japanese-Brazilians.
Materials and methods. This cross-sectional study was derived from a population-based survey on the prevalence of
diabetes and associated diseases conducted in Japanese-Brazilians. A total of 1330 male and female subjects aged 30 years
were submitted to clinical examination and laboratory procedures including homocysteine measurement. The ankle-
brachial index (ABI) was calculated; subjects with ABI values <0.9 were diagnosed with PAD. The evaluable population
included 1008 subjects. Logistic regression was used taking PAD as the dependent variable.
Results. Mean age of the population was 56.5 years and overall prevalence of PAD was 20%. A worse cardiovascular
profile was found in male patients, including significantly higher homocysteine levels (11.9 1.8 vs. 9.11.1 mmol/L,
p< 0.001). Men with PAD had higher prevalence rates of hyperhomocysteinemia compared to women (22.7% vs
7.6%). Univariate analysis showed an odds ratio of hyperhomocysteinemia for PAD of 1.51 [1.02e2.25] in men and
1.69 [1.06e2.68] in women. After adjustment for other cardiovascular risk factors, higher levels of homocysteine were
only significantly related to PAD in men.
Conclusion. In a Japanese-Brazilian population, elevated levels of homocysteine are associated with PAD in men.
Prospective studies are necessary to confirm this finding.
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The relationship betweenhomocysteine and cardiovas-
culardisorders has been extensively investigated, parti-
cularly in coronary and cerebrovascular conditions.1e5
More recently, the association between homocysteine
levels and peripheral arterial disease has also been
highlighted.6 In 1991, elevated levels of homocysteine
were proposed as a novel independent risk factor for
atherosclerotic diseases. In a case control study, subjects
with coronary, cerebral and/or peripheral atheroscle-
rosis showed elevated total homocysteine (tHcy) levels
when compared to controls.7 However, variable find-
ings were subsequently reported in different popula-
tions. A meta-analysis based on 27 observational studies
was carried out from 1976 to 1995 by Boushey et al.
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ment is 1.6 (95% confidence interval [CI], 1.4 to 1.7) for
men and 1.8 (95% CI, 1.3 to 1.9) for women. A total
of 10% of the population’s CAD risk appears
attributable to total homocysteine. The authors concl-
uded that a 5 mmol/L total homocysteine increment
elevatesCADrisk by asmuch as cholesterol increases of
0.5 mmol/L (20 mg/dL).4 Similarly, a prospective study
reported a relative risk increment of 1.41 for every
4 mmol/L increase in homocysteine concentration.8
Our group has conducted a population-based study
with Japanese immigrants and their descendants in
Brazil, since they have one of the highest prevalence
rates of glucose metabolism disturbances worldwide.9
High prevalence rates of type 2 diabetes, hypertension
and dyslipidemia in Japanese immigrants living in the
Americas10,11 suggest that the exposure to a different
lifestyle exacerbated an inherent tendency to accumu-
late body fat and increase cardiovascular risk factors.
More recently, 57% of Japanese-Brazilians were shownrved.
24 L. Garofolo et al.to have metabolic syndrome.12 Therefore, this popula-
tion represented an opportunity to investigate the
possible relationship between newly identified risk
factors, such as circulating levels of homocysteine,
and atherosclerotic cardiovascular diseases. Data coll-
ected in 2000 from the Japanese-Brazilian population
aged 30 years included Doppler of the extremities
and a number of laboratory tests.
Our aim was to investigate whether elevated levels
of homocysteine were independently associated
with peripheral arterial disease in this population of
Japanese-Brazilians with high cardiovascular risk.
Methods
A survey was conducted in a population of first
(Japan-born) and second-generation Japanese-Brazilians
living in Bauru, S~ao Paulo, Brazil, to estimate the
prevalence of diabetes and associated diseases. The
data used subsequently in this analysis belong to the sec-
ond phase of the survey, conducted in 2000. All the pa-
tients, male and female, 30 years of age were invited
to participate. Details on the selection and recruitment
of the sample population have been previously de-
scribed.13 The Institutional Ethics Committee approved
the study, and informed consent was obtained from all
the subjects. A total of 1330 subjects were interviewed
at home by trained interviewers, using standardized
health and nutritional status questionnaires, and were
scheduled for clinical and laboratory procedures. Data
on smoking status (non-smoker, current or previous
smokers, i.e. subjects who had smoked 5 or more ciga-
rettes a day for at least 12 months) and past medical
history were recorded.
The clinical examination included anthropometric
measurements. Body mass index, determined by the
weight (kilograms) divided by the square of the height
(meters); waist circumference was measured at the
umbilicus level. Blood pressure was taken after 5 min-
utes rest in the sitting position, with an automatic
device (Omron model HEM-712C, Omron Health
Care, Inc, USA). The mean of the last 2 measurements
was used to express systolic and diastolic blood pres-
sure values. Fasting blood samples were taken for
several tests. Non-diabetic and self-reported diabetic
subjects with fasting capillary glucose <200 mg/dL,
screened with glucose-oxidase strips, were submitted
to a 75-gram oral glucose tolerance test.
Conventional risk factors
Generalized and central obesity was defined accord-
ing to WHO criteria for Asian subjects.14 The cutoffs
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90 cm for men and 80 cm for women. Hypertension
was defined by systolic/diastolic blood pressure
 140/90 mmHg or use of antihypertensive medica-
tions. The diagnosis of dyslipidemia was based on
the Third Report of the National Cholesterol Educa-
tion Program e ATP III.15 Hyperuricemia was de-
fined as uric acid values above 7 mg/dL for men
and 6 mg/dL for women.16 Glucose tolerance status
was based on 1999 WHO criteria.17
Peripheral arterial disease diagnosis
The transcutaneous blood velocity detector used was
the Imbracios-8MHz Doppler. Initially, brachial occlu-
sion pressure was recorded in the supine position
with the Doppler probe placed over the brachial artery
at the elbow. The measurement was taken in both arms
and the highest value was retained. Then, ankle occlu-
sion pressure was recorded with the pencil probe
placed on the anterior and posterior tibial arteries.
The ankle-brachial index was determined in both ex-
tremities. An index below 0.90 indicated flow-limiting
stenosis in the examined leg18 and established the diag-
nosis of PAD. Subjectswith chronic renal failure (serum
creatinine> 1.6 mg/dL or clearance of 60 mL/min),19
or without complete clinical examination, laboratory
profile or ankle-brachial index data were excluded.
Therefore, data from 1008 participants (459 men and
549 women) were analyzed.
Analytical methods
Plasma glucose, creatinine and uric acid concentration
were determined by routine methods. Cholesterol
lipoprotein fractions and triglycerides were measured
by enzymatic methods in automatic analyzers. Homo-
cysteine was determined by high performance liquid
chromatography, as described by Pfeiffer et al.20
(normal range: 5e15 mmol/L) and detected by a fluori-
metric method. Plasma homocysteine levels exceed-
ing 15 mmol/L were considered to be elevated.21
Sera were stored at 70 C.
Statistical analysis
Data were reported as mean and standard deviation
for numerical variables or number and percent for cat-
egorical variables. Unpaired Student’s t test was used
to compare means of clinical and laboratory data
between subgroups stratified by gender. Chi-square
test was used for comparisons of frequencies. Non-
conditional logistic regression analysis was applied,
25Hyperhomocysteinemia and Peripheral Arterial Diseasetaking PAD as the dependent variable and hyperho-
mocysteinemia as the independent variable of main
interest, adjusted for a number of categorical variables
(conventional risk factors). Those variables with a
p value 0.20 in the crude analysis were selected for
the multivariate analysis. Distinct models were built
for each gender. Results were expressed as odds ratios
and 95% confidence intervals. The initial model for
men included age (continuous variable), smoking
habit (non-smoker, former or current smoker), glucose
tolerance status and systemic hypertension, in addi-
tion to hyperhomocysteinemia; for women, dyslipi-
demia and hyperuricemia were also included. The
level of significance was set at alpha¼ 0.05. Data anal-
yses were performed using STATA 7.0.
Results
The mean age of the 1008 Japanese-Brazilian subjects
studied (46% male) was 56.5 years. Sixty-two percent
of the population was in the 50e69 years age group;
both genders had similar age distribution (Table 1).
The mean values of body mass index, waist circum-
ference, blood pressure, fasting and 2-hour plasma
glucose, HDL-cholesterol, triglycerides, uric acid and
homocysteine were significantly higher in male
subjects.
Table 2 shows the prevalence rates of conventional
risk factors and of hyperhomocysteinemia in Japanese-
Brazilian men and women.
The prevalence of PAD was estimated at 20.4%
(95% CI [18.0%;23.1%]) for the total population
and no difference was found between genders
(19.1% vs. 20.7%, p¼ 0.529). The odds ratio for PAD
per cardiovascular risk factor is presented in Table 3.
Univariate analysis showed higher OR for PAD in
former or active smoker versus non-smoker malesubjects ( p< 0.05) (Table 3). In female subjects
aged 60 years, the presence of hypertension, diabe-
tes, hypercholesterolemia, and hypertriglyceridemia
was significantly associated with increased risk of
PAD. Hyperhomocysteinemia also increased the risk
of PAD in both genders (OR 1.51 and 1.69, respec-
tively, for men and women, p< 0.05).
The logistic regression model for males showed
that PAD was independently associated with age,
smoking habit (former and current) and hyperho-
mocysteinemia (Table 4). The risk of developing
Table 2. Prevalence rates of peripheral arterial disease risk factors
(%) by gender
Men Women Total P
Age 60 years 42.0 41.5 41.8 0.868
Smoking habit
Non-smokers 46.3 87.7 68.8 <0.001
Former smokers 34.5 4.5 18.2
Current smokers 19.2 7.8 13.0
Nutritional status
Normal 48.2 61 55.3 <0.001
Overweight 41.4 29.3 34.7
Obesity 10.4 9.7 10.0
Central obesity 42.5 46.1 44.4 0.252
Hypertension 45.2 41.2 43.0 0.219
Glucose tolerance
Normal 9.5 24.8 17.9 <0.001
Abnormal fasting
plasma glucose
25.5 19.6 22.3
Impaired glucose tolerance 26.4 25.9 26.1
Diabetes 38.6 29.7 33.7
Total cholesterol> 200 mg/dL 58.4 61.2 59.9 0.364
LDL-cholesterol> 130 mg/dL 42.5 49.7 46.4 0.022
Low HDL-cholesterol* 6.1 24.7 16.3 <0.001
Triglyceride >150 mg/dL 74.1 59.9 66.4 <0.001
Hyperuricemia** 45.1 24.9 34.1 <0.001
Hyperhomocysteinemia 22.7 7.6 14.5 <0.001
* Reference value: men, <35 mg/dL; women <45 mg/dL.
** Reference value: men, 7 mg/dl; women, 6 mg/dl.Table 1. Main characteristics of the Japanese-Brazilian population by gender
Male N¼ 459 Female N¼ 549 Total N¼ 1008 p
Age (years) 56.7 (13.1) 56.4 (12.3) 56.5 (12.7) 0.671
Body mass index (kg/m2) 25.4 (3.8) 24.5 (3.9) 24.9 (3.9) <0.001
Waist circumference (cm) 88.5 (9.8) 79.8 (9.6) 83.8 (10.6) <0.001
Systolic blood pressure (mmHg) 135.3 (23.2) 130.2 (25.0) 132.5 (24.3) <0.001
Diastolic blood pressure (mmHg) 81.3 (13.2) 76.9 (13.2) 78.9 (13.4) <0.001
Fasting plasma glucose (mg/dL) 127.0 (31.0) 120.5 (31.6) 123.5 (31.5) 0.001
2-hour plasma glucose (mg/dL) 167.1 (85.3) 154.2 (72.6) 160.1 (78.9) 0.010
Total cholesterol (mg/dL) 211.9 (42.3) 212.9 (41.0) 212.5 (41.6) 0.699
LDL-cholesterol (mg/dL) 127.3 (37.0) 129.4 (36.5) 128.5 (36.7) 0.375
HDL-cholesterol (mg/dL) 49.1 (12.1) 51.5 (10.0) 50.4 (11.0) 0.001
Triglycerides (mg/dL) 268.9 (223.5) 195.8 (132.6) 229.2 (189.2) <0.001
Uric acid (mg/dL) 7.0 (1.8) 5.3 (1.3) 6.1 (1.8) <0.001
Homocysteine (mmol/L) 11.9 (1.8) 9.1 (1.1) 10.3 (1.0) <0.001
Data expressed as means and standard deviation (in parenthesis).
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26 L. Garofolo et al.Table 3. Odds ratios of risk factors for peripheral arterial disease in Japanese-Brazilian subjects, by gender
Men Women
OR 95% CI p OR 95% CI p
Age 60 years 1.38 0.94e2.00 0.093 1.68 1.21e2.33 0.002
Smoking
Former smokers 1.80 1.13e2.86 0.012 0.93 0.42e2.08 0.862
Current smokers 2.49 1.54e4.01 0.001 0.54 0.23e1.26 0.127
Waist circumference 0.77 0.52e1.15 0.196 1.02 0.73e1.41 0.922
Hypertension 1.33 0.91e1.93 0.138 1.95 1.40e2.71 <0.001
Glucose tolerance status
Abnormal fasting plasma glucose 0.98 0.47e2.06 0.972 1.13 0.64e2.00 0.652
Impaired glucose tolerance 0.90 0.43e1.91 0.082 1.50 0.91e2.47 0.100
Diabetes 1.21 0.61e2.40 0.576 1.62 1.01e2.61 0.039
Total cholesterol> 200 mg/dL 1.19 0.80e1.75 0.384 1.56 1.08e2.24 0.015
LDL-cholesterol > 130 mg/dL 0.94 0.64e1.37 0.740 1.34 0.96e1.87 0.080
Low HDL-cholesterol* 0.54 0.18e1.61 0.241 1.08 0.75e1.57 0.668
Triglyceride >150 mg/dL 0.99 0.58e1.67 0.960 1.85 1.18e2.89 0.007
Hyperuricemia** 1.22 0.84e1.77 0.304 1.33 0.94e1.89 0.111
Hyperhomocysteinemia 1.51 1.02e2.25 0.046 1.69 1.06e2.68 0.037
* Reference value: men, <35 mg/dL; women <45 mg/d.
** Reference value: men, 7 mg/dl; women, 6 mg/dl.PAD increases 2% with each year of age (p¼ 0.02);
each increase of 1 mmol/L in the homocysteine level
was associated with a 3% increase in the risk of
developing peripheral arterial disease (p¼ 0.02).
In female subjects, the logistic regression analysis
also detected an independent association between
age (p¼ 0.04) and hypertension (p¼ 0.01) with PAD
(Table 5).
Discussion
A high prevalence of PAD (20.4%) was detected in this
population-based study of Japanese-Brazilian
subjects. Considering that this population has one of
the highest prevalence rates of diabetes worldwide12
as well as of other conventional cardiovascular risk
factors,8,22,23 they are also expected to have a high
prevalence of atherosclerotic disease.
The ankle-brachial index has been widely used as
the diagnostic tool for PAD.18,24e27 In the Limburg’s
study, using the same methodology, Stoffers et al.28
found a lower prevalence of PAD (6.1%) than in our
study, and could not detect differences in rates
between genders. Our data agree with those from
Table 4. Logistic regression model for peripheral arterial disease
in Japanese-Brazilian men
Odds ratio 95% CI P value
Age 1.02 1.00e1.04 0.02
Former smokers 1.82 1.03e3.21 0.04
Current smokers 3.22 1.76e6.04 0.01
Hyperhomocysteinemia 1.03 1.00e1.06 0.02
CI, confidence interval.
Eur J Vasc Endovasc Surg Vol 34, July 2007the Rotterdam study, where prevalence rates were
approximately 17% in male and 20% in female sub-
jects above age 55.26
More recent data from the National Health and
Nutrition Examination Survey29 found PAD was pre-
sent in 4.3% of the North American population above
40 years and in 14.5% above 70 years. Murabito et al.30
found similar data analyzing 1554 men and 1759
women included in the Framingham study. Using
the ankle-brachial index for diagnosing PAD,
their prevalence rate was 3.9% in men and 3.3% in
women. Despite these lower rates, again there was
no difference between genders. The high incidence
of conventional risk factors in both genders might
contribute to similar rates of PAD in Japanese-
Brazilian men and women.
Using multivariate analysis, we found a number
of risk factors associated with PAD for each gender.
Age was associated with PAD in men and women.
Smoking and hyperhomocysteinemia were only asso-
ciated with PAD in men. In fact, the prevalence of
smoking among women was low. Even with the
low prevalence of smoking among women, we found
a similar prevalence of PAD in both sexes; therefore,
the high prevalence of PAD in women may be
Table 5. Logistic regression model for peripheral arterial disease
in Japanese-Brazilian women
Odds ratio 95% CI P value
Age 1.57 1.02e2.44 0.04
Hypertension 2.05 1.32e3.18 0.01
CI, confidence interval.
27Hyperhomocysteinemia and Peripheral Arterial Diseaseinfluenced by hyperhomocysteinemia. Univariate
analysis of risk factors in women showed an odds
ratio of hyperhomocysteinemia for PAD of 1.69
(1.06e2.68).
Homocysteine concentration, as well as the pre-
valence of hyperhomocysteinemia, were lower in
Japanese-Brazilian women than in men. These find-
ings are similar to those obtained in a smaller study,
including 32 women and 29 men with PAD.31 The in-
vestigators found significantly higher levels of homo-
cysteine among men (18.3 mmol/L) as compared to
women (15.3 mmol/L). No association between PAD
and hyperhomocysteinemia in the female subjects
was also demonstrated in another investigation.32
Loncar et al.33 compared homocysteine levels of
40 subjects with PAD and 40 healthy volunteers, and
found higher mean values in affected subjects
(14.8 mmol/L vs 11.3 mmol/L). Differences in homocys-
teine concentrations between genders were observed in
the control group, with significantly higher values in
healthy men than in healthy women (12.05 mmol/L
vs 9.63 mmol/L). Such influence of gender on homocys-
teine levels was first described by Cacan et al.34 in a
healthy study population; mean values of 9.7 mmol/L
in men were shown to be significantly higher than
in women (7.6 mmol/L). A plausible explanation for
this difference was proposed by Dierkes et al.35 who
suggested that high levels of estradiol and low per-
centage of lean body mass could contribute to lower
homocysteine levels in female subjects.
We defined hyperhomocysteinemia as plasma
homocysteine levels above 15 mmol/L.We did not con-
sider the influence of gender on homocysteine levels,
which may have interfered with the low prevalence
of female hyperhomocysteinemia. In our cross-
sectional study, the prevalence of PAD in Japanese-
Brazilian men increased 3% for each 1 mmol/L
elevation in homocysteine concentration. These data
are similar to those reported in the Homocysteine and
Progression of Atherosclerosis Study.36 This prospective
study concluded that an elevation of 1 mmol/L in
serum homocysteine increased by 3.6% the risk of
death from PAD. A recent review37 confirmed that
the odds ratio for PAD in subjects with hyperhomocys-
teinemia varies considerably, ranging from 2.0 to 11.0.
Clarke et al.7 were the first to report that hyperho-
mocysteinemia could be an independent risk factor
for atherosclerosis. In subjects with hyperhomocystein-
emia, they found different odds ratios, depending on
the arterial territory studied: 1.52 for extracranial
carotid-artery, 1.40 for coronary artery and 1.13 for
peripheral arteries. The hypothesis that hyperhomo-
cysteinemia could be a novel atherosclerotic risk fac-
tor was contested by Valentine et al.,38 who did notfind any difference in homocysteine values comparing
young men with and without PAD.
The Nutrition Examination Survey (NHANES),39
a cross-sectional study, evaluated the roles of tradi-
tional and non traditional risk factors, including
lead and cadmium exposure, in confounding the
association between homocysteine and reduced ankle-
brachial index. The findings indicate that previous
studies may have overestimated the association
betweenhomocysteine andPAD.Adjustment for blood
lead and cadmium and for smoking completely elimi-
nated the association of homocysteine with PAD. On
the contrary, our study found independent associations
of homocysteine and smoking with PAD in men.
In conclusion, our data supports an independent
association of PAD and hyperhomocysteinemia in
Japanese-Brazilian male subjects. The study design
does not allow a causal relationship to be assigned.
To find out if an elevated homocysteine level repre-
sents an additional risk factor for this population, pro-
spective studies are required, perhaps considering
different normal ranges for men and women.
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